KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Return on Sales (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Return on Sales data on record, last reported at 0.9% in Q4 2025.

  • For Q4 2025, Return on Sales fell 96.0% year-over-year to 0.9%; the TTM value through Dec 2025 reached 3.41%, down 140.0%, while the annual FY2025 figure was 3.41%, 140.0% down from the prior year.
  • Return on Sales reached 0.9% in Q4 2025 per PACB's latest filing, up from 0.99% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.47% in Q3 2021 and bottomed at 11.47% in Q1 2025.
  • Average Return on Sales over 5 years is 2.15%, with a median of 1.49% recorded in 2024.
  • The widest YoY moves for Return on Sales: up 376bps in 2025, down -945bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 1.92% in 2021, then crashed by -60bps to 3.08% in 2022, then skyrocketed by 54bps to 1.41% in 2023, then surged by 104bps to 0.06% in 2024, then crashed by -1596bps to 0.9% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 0.9% in Q4 2025, 0.99% in Q3 2025, and 1.05% in Q2 2025.